$52.73
−0.01%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$52.35
From 52W high−7.95%
Volume3.52M
Market cap$32.43B
P/E (TTM)41.3x
P/S (TTM)7.8x
Div yield—
Key dataNov 6, 2026
Open
$52.35
From 52W high
−7.95%
Volume
3.52M
Market cap
$32.43B
ValuationView details →
P/E (Fwd)
33.1x
EV/EBITDA
29.7x
P/E (TTM)
41.3x
RSI (14)
69.1
MomentumView details →
1D Return
−0.01%
YTD Return
+70.99%
SummaryUpdated Jun 1, 2026
Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.
Similar companies
Latest newsMore news →
GENMAB A/S shares rose during a breakout week, adding about $10 billion in market value, amid stellar cancer-drug data.7d agoGENMAB A/S shares surged to a record high.9d agoGENMAB A/S announced positive topline results from the Phase 3 LiGeR-HN1 trial, reporting that petosemtamab plus pembrolizumab met both primary endpoints and reduced the risk of death by 50% versus pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma.9d ago